Anyo Labs Introduces NOVA

• Gothenburg, Sweden

Anyo Labs, today announced the launch of its groundbreaking NOVA nano-cluster, setting a new standard for efficiency and targeted computational hardware for the pharmaceutical industry. While others focus on building the largest supercomputers for drug discovery, Anyo Labs introduces the smallest, demonstrating that immense power for intelligent drug engineering can come in an incredibly efficient package.

Under the hood

The Anyo Labs NOVA combines a carrier board housing 4 NVIDIA Jetson modules combined with an x86 SOC, all within a remarkably compact 240mm x 240mm x 100mm form factor (less than 6 liters in volume). This system achieves an extraordinary screening rate of 1,000 molecules per second against specific protein targets, all while consuming less than 150 watts of power. This remarkable performance is enabled by Anyo Labs' unique, proprietary Machine Learning (ML) and Deep Learning models, meticulously tailored to balance exceptional accuracy with unprecedented speed for effective drug engineering.

"The race in pharmaceutical computing shouldn't just be about sheer scale; it must be about targeted impact and efficiency," said Albin Boman, CEO at Anyo Labs. "Building massive, power-hungry systems isn't the only path forward. We've focused on developing highly optimized, proprietary AI models that allow us to achieve incredible drug engineering throughput with our NOVA system. Its ultra-compact size and low power draw prove that smarter, focused computation can be more powerful than just bigger computation."

"The race in pharmaceutical computing shouldn't just be about sheer scale; it must be about targeted impact and efficiency," - Albin Boman CEO

A Paradigm Shift

Unlike large-scale systems requiring significant infrastructure and energy, the Anyo Labs NOVA offers a paradigm shift. Its miniature size and low power consumption make powerful computational drug engineering accessible and sustainable. This approach allows for rapid, targeted screening, accelerating the identification of potential drug candidates by focusing computational power where it matters most – on engineering effective solutions.

"Our proprietary ML models are the key," stated André Stadelmann, CTO. "They are specifically designed for NOVA, maximizing the potential of each calculation. We're not just running algorithms; we're running highly optimized engineering engines capable of sifting through vast chemical spaces with unparalleled speed and energy efficiency, directly challenging the notion that only the largest systems can drive innovation."

Anyo Labs is redefining the future of computational drug engineering by proving that intelligence and efficiency, not just size, will accelerate the development of new medicines.